Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Lancet

• Publication date

  2007-07-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(07)61124-6PMID 17658393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

  2007cited by this paper
• Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.

  2007cited by this paper
• The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

  2006cited by this paper
• Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial

  2006cited by this paper
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

  2005cited by this paper
• Renin inhibition: what are the therapeutic opportunities?

  2005cited by this paper
• Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

  2005cited by this paper
• Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients

  2005cited by this paper
• Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

  2005cited by this paper
• Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.

  2005cited by this paper
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

  2005cited by this paper
• Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

  2005cited by this paper
• Antihypertensive Efficacy of Candesartan‐Lisinopril in Combination vs. Up‐Titration of Lisinopril: The AMAZE Trials

  2004cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

  2004cited by this paper
• Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.

  2004cited by this paper
• Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy

  2004cited by this paper
• Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists

  2004cited by this paper
• Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

  2003cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril

  2002cited by this paper
• Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  2000cited by this paper
• Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.

  1998cited by this paper
• Changes in Endocrine Activities Relative to Obesity in Patients with Essential Hypertension *

  1981cited by this paper
• Inhibition of Renin Secretion by Angiotensin .II.∗

  1965cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review.

  2025cites this paper
• Renin inhibitors versus angiotensin receptor blockers for primary hypertension.

  2025cites this paper
• A Basic Review on Hypertension, its Non-Pharmacological and Pharmacological Treatment

  2024cites this paper
• Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension—the Importance of a Mechanistic, Personalized Approach

  2024cites this paper
• Role of hypertension in progression of pediatric CKD

  2023cites this paper
• Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.

  2022cites this paper
• Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus

  2022cites this paper
• Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review

  2021cites this paper
• Role of angiotensin II in the development of subcellular remodeling in heart failure

  2021cites this paper
• Intratubular, Intracellular, and Mitochondrial Angiotensin II/AT1 (AT1a) Receptor/NHE3 Signaling Plays a Critical Role in Angiotensin II-Induced Hypertension and Kidney Injury

  2021cites this paper
• A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine

  2021cites this paper
• An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension

  2020cites this paper
• Dual renin‐angiotensin‐aldosterone blockade: Implementation of published research and Dear Doctor letters in ambulatory care: A retrospective observational study using prescription data

  2020cites this paper
• Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial.

  2020cites this paper
• Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras)

  2020cites this paper
• Antihypertensive Drugs and Vasodilators

  2019cites this paper
• Effects of sleep extension on sleep duration, sleepiness, and blood pressure in college students.

  2019cites this paper
• The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis

  2019cites this paper
• 2018 Chinese Guidelines for Prevention and Treatment of Hypertension—A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension

  2019cites this paper
• Treatment of Hypertension in Chronic Kidney Disease

  2019cites this paper
• The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor

  2019cites this paper
• Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys.

  2019cites this paper
• Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.

  2018cites this paper
• Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension

  2018cites this paper
• Evaluation of Blood Pressure Control Medicines Using Health and Medical Checkup Data in Japan: Alternative Methods for Randomized Controlled Trials

  2018cites this paper
• Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

  2017influential citation
• Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus.

  2017cites this paper
• Resistant hypertension: Definition, evaluation, and new therapeutic approaches to treatment

  2017cites this paper
• Blood pressure lowering efficacy of renin inhibitors for primary hypertension.

  2017cites this paper
• The Angiotensin-Converting-Enzyme-Induced Angioedema.

  2017cites this paper
• Quantitative characterization of optic nerve atrophy in patients with multiple sclerosis

  2017cites this paper
• Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension

  2017cites this paper
• Renin Inhibition with Aliskiren: A Decade of Clinical Experience

  2017cites this paper
• Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry

  2016cites this paper
• Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck

  2016cites this paper
• Evidenz und Evidenzlücken für medikamentös zu behandelnde, nicht-tumoröse Erkrankungen im Gebiet der HNO-Heilkunde

  2016cites this paper
• Progression of Chronic Kidney Disease and Nephroprotective Therapy

  2016cites this paper
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

  2016cites this paper
• Inhibiteurs du système rénine-angiotensine

  2016cites this paper
• Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation

  2015cites this paper
• A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness

  2015cites this paper
• Development of hypertension – clinical impact of dysregulation of circadian rhythms and implications for treatment

  2015cites this paper
• Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D

  2015cites this paper
• Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria

  2015cites this paper
• Effect of aliskiren on vascular remodelling in small retinal circulation

  2015cites this paper
• Direct injection human plasma analysis for the quantification of antihypertensive drugs for therapeutic drug monitoring using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry.

  2015cites this paper
• The importance of gastrointestinal hormones in the development of obesity-related hypertension

  2015cites this paper
• Aliskiren –An overview

  2015cites this paper
• Can Aliskiren be Considered as a New Novel Drug for Hypertension?

  2015cites this paper
• Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats

  2014cites this paper
• Renin inhibitors in diabetes and hypertension: an update

  2014influential citation
• THEORY OF DENERVATION AND BLOOD PRESSURE EFFECTS Pathobiology of Resistant Hypertension

  2014cites this paper
• A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

  2014cites this paper
• Promoting higher blood pressure targets for frail older adults: A consensus guideline from Canada

  2014cites this paper
• Evolución de la enfermedad cardiorrenal bajo la supresión crónica del sistema renina-angiotensina

  2014cites this paper
• The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry

  2014cites this paper
• Effects of antihypertensive therapy on glucose, insulin metabolism, left ventricular diastolic dysfunction and renin system in overweight and obese hypertensives

  2014cites this paper
• Update on role of direct renin inhibitor in diabetic kidney disease

  2014cites this paper
• Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists

  2014cites this paper
• Sympathetic activation in resistant hypertension: theory and therapy.

  2014cites this paper
• [Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies].

  2014cites this paper
• Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial

  2014cites this paper
• I Brazilian Position Paper on Antihypertensive Drug Combination

  2014cites this paper
• [Combined blockade of the renin-angiotensin system].

  2014cites this paper
• Antiproteinuric Effect of Aliskiren versus Losartan in Primary Glomerulonephritis

  2014cites this paper
• Antiproteinuric Effect of Sulodexide versus Losartan in Primary Glomerulonephritis

  2014cites this paper
• Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics: Aliskiren and Valsartan Impact in Diabetics Pilot Trial

  2014cites this paper
• Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.

  2014cites this paper
• Aliskiren and losartan trial in non-diabetic chronic kidney disease

  2014cites this paper
• Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls

  2014cites this paper
• PROSPECTS FOR THE USE OF DIRECT RENIN INHIBITOR ALISKIREN FOR THE TREATMENT OF SOCIALLY SIGNIFICANT DISEASES

  2014cites this paper
• I Posicionamento Brasileiro sobre Combinação de Fármacos Anti-Hipertensivos

  2014cites this paper
• A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.

  2014cites this paper
• Calcium Channel BlockersDirect Renin Inhibitors (DRI) as Novel Antihypertensive Agents

  2014cites this paper
• THE NEPHROPROTECTIVE EFFECT OF ANTIHYPERTENSIVE TREATMENT

  2014cites this paper
• Combined blockade of the renin-angiotensin system Key-words (Index medicus): Renin. Hypertension. Diabetes Mellitus. Cardio- vascular Diseases

  2014cites this paper
• A guide for easy- and difficult-to-treat hypertension.

  2014cites this paper
• Efficacy and safety profile of aliskiren: practical implications for clinicians.

  2014cites this paper
• Sequential RAAS blockade: is it worth the risk?

  2014cites this paper
• COMBINATION TECHNOLOGY FOR TREATMENT OF HYPERTENSION: A REVIEW

  2013cites this paper
• Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

  2013cites this paper
• Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease

  2013cites this paper
• Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus

  2013cites this paper
• Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis

  2013cites this paper
• No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

  2013cites this paper
• An evaluation of the latest evidence relating to renin–angiotensin system inhibitors

  2013cites this paper
• It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems

  2013cites this paper
• Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin

  2013influential citation
• Hypertension- a paradox-The challenges and newer perspectives of Treatment

  2013cites this paper
• Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis

  2013cites this paper
• Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.

  2013cites this paper
• Der Stellenwert des Renin-Inhibitors Aliskiren

  2013cites this paper
• Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus

  2013cites this paper
• Der Stellenwert des Renin-Inhibitors Aliskiren

  2013cites this paper
• Optimization and validation of a MEKC method assisted by Box–Behnken Design for fast and simultaneous determination of nitrendipine and atenolol in new antihypertensive combination tablets

  2013cites this paper
• Direct renin inhibition – a promising strategy for renal protection?

  2013cites this paper
• Chapter 6 – Vascular Pharmacology

  2013cites this paper
• How are physicians prescribing the direct renin inhibitor aliskiren in the management of essential hypertension? A French observational study

  2013cites this paper
• Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials

  2013influential citation
• Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?

  2013cites this paper